Literature DB >> 22357405

Executive dysfunction and memory impairment in schizoaffective disorder: a comparison with bipolar disorder, schizophrenia and healthy controls.

B Amann1, J J Gomar, J Ortiz-Gil, P McKenna, B Sans-Sansa, S Sarró, N Moro, M Madre, R Landin-Romero, E Vieta, J M Goikolea, J M Giokolea, R Salvador, E Pomarol-Clotet.   

Abstract

BACKGROUND: Deficits in memory and executive performance are well-established features of bipolar disorder and schizophrenia. By contrast, data on cognitive impairment in schizoaffective disorder are scarce and the findings are conflicting.
METHOD: We used the Wechsler Memory Scale (WMS-III) and the Behavioural Assessment of the Dysexecutive Syndrome (BADS) to test memory and executive function in 45 schizophrenic patients, 26 schizomanic patients and 51 manic bipolar patients in comparison to 65 healthy controls. The patients were tested when acutely ill.
RESULTS: All three patient groups performed significantly more poorly than the controls on global measures of memory and executive functioning, but there were no differences among the patient groups. There were few differences in memory and executive function subtest scores within the patient groups. There were no differences in any test scores between manic patients with and without psychotic symptoms.
CONCLUSIONS: Schizophrenic, schizomanic and manic patients show a broadly similar degree of executive and memory deficits in the acute phase of illness. Our results do not support a categorical differentiation across different psychotic categories with regard to neuropsychological deficits.

Entities:  

Mesh:

Year:  2012        PMID: 22357405     DOI: 10.1017/S0033291712000104

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  8 in total

1.  Examining cognition across the bipolar/schizophrenia diagnostic spectrum.

Authors:  Amy J Lynham; Leon Hubbard; Katherine E Tansey; Marian L Hamshere; Sophie E Legge; Michael J Owen; Ian R Jones; James T R Walters
Journal:  J Psychiatry Neurosci       Date:  2018-04-05       Impact factor: 6.186

2.  Examining cognition across the bipolar/schizophrenia diagnostic spectrum.

Authors:  Amy J Lynham; Leon Hubbard; Katherine E Tansey; Marian L Hamshere; Sophie E Legge; Michael J Owen; Ian R Jones; James T R Walters
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

3.  Predicting Cognitive Executive Functioning with Polygenic Risk Scores for Psychiatric Disorders.

Authors:  Chelsie E Benca; Jaime L Derringer; Robin P Corley; Susan E Young; Matthew C Keller; John K Hewitt; Naomi P Friedman
Journal:  Behav Genet       Date:  2016-10-14       Impact factor: 2.805

4.  Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different.

Authors:  A Owoso; C S Carter; J M Gold; A W MacDonald; J D Ragland; S M Silverstein; M E Strauss; D M Barch
Journal:  Psychol Med       Date:  2013-03-25       Impact factor: 7.723

Review 5.  The global cognitive impairment in schizophrenia: consistent over decades and around the world.

Authors:  Jonathan Schaefer; Evan Giangrande; Daniel R Weinberger; Dwight Dickinson
Journal:  Schizophr Res       Date:  2013-08-02       Impact factor: 4.939

6.  Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study.

Authors:  S Kristian Hill; James L Reilly; Michael E Ragozzino; Leah H Rubin; Jeffrey R Bishop; Ruben C Gur; Elliot S Gershon; Carol A Tamminga; Godfrey D Pearlson; Matcheri S Keshavan; Richard S E Keefe; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-09-05       Impact factor: 9.306

7.  Autism spectrum disorder polygenic scores are associated with every day executive function in children admitted for clinical assessment.

Authors:  Tonje Torske; Terje Naerland; Francesco Bettella; Thomas Bjella; Eva Malt; Anne Lise Høyland; Nina Stenberg; Merete Glenne Øie; Ole A Andreassen
Journal:  Autism Res       Date:  2019-09-30       Impact factor: 5.216

8.  Using the MMSE-2 to Measure Cognitive Deterioration in a Sample of Psychiatric Patients Living in Puerto Rico.

Authors:  Sandra I Ralat
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.